IP Library Granted Patent US 8,012,744
Granted Patent B2
US 8,012,744 · App. 11/549,558 · Granted Sep 6, 2011

Reducing optical interference in a fluidic device

Assignee: Theranos, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,012,744
App. No.
11/549,558
Granted
Sep 6, 2011
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.

Claims (30)

1. A fluidic device having a housing and being configured to run an immunoassay for detecting an analyte in a sample of bodily fluid within said housing comprising:

(a) a sample collection unit adapted to provide a sample of bodily fluid into said fluidic device;

(b) an assay assembly in fluidic communication with said sample collection unit, said assay assembly comprising:

(i) a reagent chamber comprising at least one reagent used in said assay; and

(ii) at least one reaction site comprising a reactant that binds said analyte, wherein said assay assembly is adapted to yield a luminescent signal indicative of the presence of the analyte in the sample of bodily fluid, and wherein the at least one reagent reacts with a second reagent in said assay assembly to produce an optical signal; and

(c) a quencher assembly, in fluidic communication with but separated by a channel from said assay assembly, comprising a quenching agent that inhibits an enzymatic reaction between the at least one reagent and the second reagent in said quencher assembly, thereby reducing interference with said luminescent signal.

2. The fluidic device of claim 1 , wherein said at least one reagent comprises an enzyme conjugate or an enzyme substrate.

3. The fluidic device of claim 1 , wherein said quencher assembly comprises a quenching site in fluidic communication with said reaction site and the quenching agent at said quenching site.

4. The fluidic device of claim 3 , wherein said quencher assembly further comprises an absorbent material.

5. The fluidic device of claim 4 , wherein said absorbent material is impregnated with said quenching agent.

6. The fluidic device of claim 4 , wherein said absorbent material is selected from the group consisting of glass fiber, silica, paper, polyacrylamide gel, agarose, and agar.

7. The fluidic device of claim 4 , wherein said quenching agent is a denaturing agent.

8. The fluidic device of claim 7 , wherein said quenching agent is 4-amino-1,11-azobenzene-3,41-disulfonic acid.

9. The fluidic device of claim 1 , wherein said assay assembly is adapted to run a chemiluminescent assay.

10. The fluidic device of claim 1 , wherein said quencher assembly is adapted to substantially eliminate said interference.

11. The fluidic device of claim 3 , further comprising a waste chamber, wherein said waste chamber comprises said quenching site.

12. The fluidic device of claim 1 , wherein said sample of bodily fluid is blood.

13. A fluidic device for detecting an analyte in a sample, comprising:

a sample collection unit;

an assay assembly comprising at least one reaction site, said reaction site comprising a surface and immobilized thereon a reactant that forms a complex comprising the analyte;

a first reagent chamber comprising an enzyme conjugate;

a second reagent chamber comprising an enzyme substrate, wherein the enzyme substrate reacts with the enzyme conjugate to produce a chemiluminescent signal; and

fluidic channels that connect the reagent chambers with the at least one reaction site;

a quencher assembly at a separate location from the assay assembly, the quencher assembly comprising an absorbent material and a quenching agent, wherein the quenching agent inhibits the chemiluminescent reaction between the enzyme conjugate and the enzyme substrate; and

a plurality of fluidic channels that connect the sample collection unit and the quencher assembly with the assay assembly.

14. The fluidic device of claim 13 , wherein said quencher assembly further comprises a waste chamber connected through a fluid channel with the assay assembly, wherein the waste chamber comprises the absorbent material.

15. The fluidic device of claim 13 , wherein said absorbent material is selected from the group consisting of glass fiber, silica, paper, polyacrylamide gel, agarose, or agar.

16. The fluidic device of claim 15 , wherein said quenching agent is 4-amino-1,11-azobenzene-3,41-disulfonic acid and said conjugate is an alkaline phosphatase-labeled reagent.

17. The fluidic device of claim 13 , wherein said assay assembly is adapted to run an immunoassay.

18. The fluidic device of claim 1 wherein said luminescent signal is a chemiluminescent signal.

Assignments (5)
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045101/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2007
From: GIBBONS, IAN; O'CONNELL, MICHAEL
To: THERANOS, INC.
Reel/Frame 019029/0343 →
Continuity (1)
Related Publication 20080090256A1 · Apr 17, 2008